About Us

Rich Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of its lead product, TPA, (12-O- tetradecanoyl- phorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in these and possibly other indications is the result of the Prof. Richard Chang.  He has conducted research on TPA for many years and have become an expert in the characteristics of this molecule. Their findings form the scientific basis for the clinical use of TPA. » Read more about us

Latest News

July 18

Rich Pharmaceuticals Announces Collaboration Agreement To Support The Development of Treatments For Parkinson’s Disease: Company Will Receive Cash and Stock and Plans to Pay One Third of the Shares Received in a Dividend to Shareholders View Release

June 21

Rich Pharmaceuticals Announces Principal Doctor for Clinical Trials View Release

June 8

Rich Pharmaceuticals Announces Institutional Review Board Submission View Release

» Read Latest News